NantKwest (NASDAQ:NK) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership.
Institutional & Insider Ownership
9.4% of NantKwest shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 71.7% of NantKwest shares are held by company insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares NantKwest and Halozyme Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
NantKwest | -76,658.58% | -56.06% | -46.93% |
Halozyme Therapeutics | 10.78% | 24.29% | 4.08% |
Analyst Ratings
This is a summary of current recommendations and price targets for NantKwest and Halozyme Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
NantKwest | 0 | 0 | 1 | 0 | 3.00 |
Halozyme Therapeutics | 0 | 1 | 9 | 0 | 2.90 |
NantKwest presently has a consensus target price of $18.00, suggesting a potential upside of 6.70%. Halozyme Therapeutics has a consensus target price of $42.9167, suggesting a potential upside of 0.34%. Given NantKwest's stronger consensus rating and higher possible upside, equities research analysts clearly believe NantKwest is more favorable than Halozyme Therapeutics.
Risk & Volatility
NantKwest has a beta of 2.61, indicating that its stock price is 161% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Earnings and Valuation
This table compares NantKwest and Halozyme Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
NantKwest | $40,000.00 | 46,116.25 | $-65,790,000.00 | ($0.70) | -24.10 |
Halozyme Therapeutics | $195.99 million | 31.27 | $-72,240,000.00 | ($0.50) | -85.54 |
NantKwest has higher earnings, but lower revenue than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than NantKwest, indicating that it is currently the more affordable of the two stocks.
Summary
Halozyme Therapeutics beats NantKwest on 8 of the 14 factors compared between the two stocks.